Use of recombinant factor VIIa in inherited platelet disorders
نویسندگان
چکیده
منابع مشابه
Use of Recombinant factor VIIa in Obstetrics
6 The objective of this review article was to evaluate the current literature on the increasing off-label use of rFVIIa in the management of critical obstetric hemorrhage. Given the lack of high-level evidence, there is a need to review the clinical indications, observed response and adverse events. This review is designed to aid practitioners in deciding when and how to administer rFVIIa; It m...
متن کاملThe Use of Recombinant Factor VIIa*
As described in detail in other chapters of this volume, conditions with excessive bleeding, as are seen with uterine rupture, placenta accreta, abruption and uterine atony, often require intensive resuscitation with blood components and coagulation factors. In such circumstances, blood transfusion may be life-saving, but on occasion involves exposing the patient to additional risks. Over the y...
متن کاملTreatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?
The mechanism of action of recombinant factor VIIa (rFVIIa), i.e. increased thrombin generation on the membrane of activated platelets, as well as the results from in vitro and ex vivo models of thrombocytopenia or inherited thrombocytopathia may support some potential of rFVIIa in thrombocytopenia/thrombocytopathia. rFVIIa was reported as effective to stop or to decrease bleeding in few patien...
متن کاملReview in translational hematology The use of recombinant factor VIIa in the treatment of bleeding disorders
Recombinant factor VIIa was initially developed for the treatment of hemorrhagic episodes in hemophilic patients with inhibitors to factors VIII and IX. After its introduction, it has also been used “off-label” to enhance hemostasis in nonhemophilic patients who experience bleeding episodes not responsive to conventional therapy. Evidence so far indicates that the use of factor VIIa in hemophil...
متن کاملThe use of recombinant factor VIIa in the treatment of bleeding disorders.
Recombinant factor VIIa was initially developed for the treatment of hemorrhagic episodes in hemophilic patients with inhibitors to factors VIII and IX. After its introduction, it has also been used "off-label" to enhance hemostasis in nonhemophilic patients who experience bleeding episodes not responsive to conventional therapy. Evidence so far indicates that the use of factor VIIa in hemophil...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2004
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2004.04878.x